2015
DOI: 10.1186/s40064-015-1217-y
|View full text |Cite
|
Sign up to set email alerts
|

A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients

Abstract: Desmopressin (dDAVP) is a well-known peptide analog of the antidiuretic hormone vasopressin, used to prevent excessive bleeding during surgical procedures. dDAVP increases hemostatic mediators, such as the von Willebrand factor (vWF), recently considered a key element in resistance to metastasis. Studies in mouse models and veterinary trials in dogs with locally-advanced mammary tumors demonstrated that high doses of perioperative dDAVP inhibited lymph node and early blood-borne metastasis and significantly pr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
23
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 34 publications
(24 citation statements)
references
References 31 publications
(41 reference statements)
0
23
1
Order By: Relevance
“…Intriguingly, the antibody treatment cured metastasis in 30% of the experimental mice, enabling them to accomplish their life free from cancer cells. Recent report on a phase II dose-escalation trial of desmopressin in breast cancer patients has demonstrated that administration of desmopressin, which stimulates the release of VWF from endothelial cells (31), reduces circulating cancer cells by increasing blood levels of VWF (32). Altogether, it is plausible to think that our antibody is useful for prevention of micrometastases by extinguishing circulating cancer cells, which are commonly detected in cancer patients, including NSCLC patients (33).…”
Section: Discussionmentioning
confidence: 94%
“…Intriguingly, the antibody treatment cured metastasis in 30% of the experimental mice, enabling them to accomplish their life free from cancer cells. Recent report on a phase II dose-escalation trial of desmopressin in breast cancer patients has demonstrated that administration of desmopressin, which stimulates the release of VWF from endothelial cells (31), reduces circulating cancer cells by increasing blood levels of VWF (32). Altogether, it is plausible to think that our antibody is useful for prevention of micrometastases by extinguishing circulating cancer cells, which are commonly detected in cancer patients, including NSCLC patients (33).…”
Section: Discussionmentioning
confidence: 94%
“…More recently, a phase II dose-escalation trial in women with breast cancer was performed, demonstrating that DDAVP, administered 30–60 min before and 24 h after surgical resection, reduced intraoperative bleeding and the number of circulating tumor cells. Moreover, it appeared to be safe and well tolerated at the highest dose level evaluated (2 µg/kg) (37). …”
Section: Discussionmentioning
confidence: 99%
“…A recent clinical trial in breast cancer patients administered with perioperative infusions of dDAVP demonstrated a reduced intrasurgical bleeding with increasing doses of the compound. Interestingly, treatment was associated with higher VWF plasma levels and a postoperative decrease in circulating tumor cell counts [14].…”
Section: Introductionmentioning
confidence: 99%